Glossary · GHRH analog
CJC-1295 DAC
Also known as: Modified GRF with DAC · CJC-1295 w/ DAC · CJC 1295 DAC · CJC1295 · CJC1295 DAC · DAC CJC-1295
- Class
- GHRH analog
- Half-life
- ~7–8 days (DAC variant, albumin-bound)
- Typical dose
- 1–2 mg/week
- Route
- subq
Mechanism
CJC-1295 DAC is a synthetic GHRH analog carrying a albumin-binding modification (DAC) linker — a lysine residue modified to bind covalently to circulating serum albumin. That albumin bond is what extends the otherwise short half-life of GHRH fragments from minutes to roughly 7–8 days. The practical result is a persistent, low-amplitude elevation of baseline GH across the entire week from a single injection, rather than the brief spike you get from non-DAC GHRH analogs.
That sustained baseline is important context for dosing logic: CJC-1295 DAC raises the ceiling on GH pulses but does not trigger them. The pituitary still needs a GHRP signal — ipamorelin, GHRP-6, or similar — to fire an actual pulsatile release. Running CJC-1295 DAC alone produces a slow, blunted GH bleed. Pairing it with a GHRP is what converts that elevated ceiling into meaningful, physiologically patterned pulses. Most protocols treat the CJC as the background and the GHRP as the trigger.
Because the DAC linker keeps the peptide active for days, the pituitary GHRH receptor is under sustained stimulation — which carries a small downregulation risk on very long cycles. This is the main trade-off versus short-acting GHRH analogs like sermorelin: the once-a-week convenience comes with a longer receptor recovery requirement during the off period.
Typical protocol
- Starter: 1 mg SC once weekly. Run alongside ipamorelin 200–300 mcg 2×/day (pre-bed and post-workout).
- Advanced: 2 × 500 mcg/week split Mon/Thu. Paired with ipamorelin 250 mcg 3×/day (fasted AM, post-workout, pre-bed).
- Cycle length: 8–12 weeks on / 4 weeks off. Do NOT stack with a non-DAC CJC (Mod GRF 1-29) — redundant, same mechanism.
- Reconstitution: 2 mg vial + 1 mL bacteriostatic water → 2 mg/mL. 50 IU on a U-100 insulin syringe = 0.5 mL = 1 mg.
Who it's for
Muscle growth (recomposition) and recovery users who want a sustained GH baseline without daily injections — the once-a-week schedule is the main practical advantage over non-DAC analogs. Also fits longevity stacks where a low continuous GH elevation is the goal rather than peak pulses. Best suited to experienced users who already understand GHRP stacking and can recognize early side effects while the peptide is still clearing.
Stacks well with
- ipamorelin 5mg — mandatory GHRP pairing. CJC raises the pulse ceiling, ipamorelin triggers clean pulses against it.
- ghrp 6 5mg — alternative GHRP with appetite stimulation, better for bulking phases.
- recomp stack cjc ipamorelin aod — pre-bundled stack combining CJC + ipamorelin + AOD-9604 for body recomposition.
Watch-outs
- Any side effect (lethargy, numb extremities, water retention) persists for days because of the week-long half-life. Start conservative and give the first dose time to reveal tolerability before escalating.
- Fasting insulin can creep during long cycles; monitor if running alongside aggressive carb protocols.
- Do NOT stack with Mod GRF 1-29 or other non-DAC GHRH analogs — redundant mechanism, wastes the second product.
About CJC-1295 DAC
What is CJC-1295 DAC?
CJC-1295 DAC is a synthetic GHRH analog carrying a albumin-binding modification (DAC) linker — a lysine residue modified to bind covalently to circulating serum albumin. That albumin bond is what extends the otherwise short half-life of GHRH fragments from minutes to roughly 7–8 days.
What is the half-life of CJC-1295 DAC?
Plasma half-life of CJC-1295 DAC is reported at ~7–8 days (DAC variant, albumin-bound). This is a research-reference figure derived from published pharmacokinetic studies — administration timing and dosing intervals in published protocols are designed around this value.
What is the typical research dose range for CJC-1295 DAC?
Published research-protocol ranges for CJC-1295 DAC fall between 1–2 mg/week, administered subcutaneously. These figures reference research-literature dosing only — they are not a clinical recommendation and CJC-1295 DAC is supplied here strictly as a research reagent.
What class of compound is CJC-1295 DAC?
CJC-1295 DAC belongs to the GHRH analog class of research peptides. It is also referred to in the literature as Modified GRF with DAC or CJC-1295 w/ DAC. Each GHRH analog compound shares overlapping pharmacology but differs in receptor selectivity, half-life, and reported research applications.
What is the typical research-protocol cycle for CJC-1295 DAC?
Starter: 1 mg SC once weekly. Run alongside ipamorelin 200–300 mcg 2×/day (pre-bed and post-workout).
Catalog note
CJC-1295 DAC is not currently stocked
CJC-1295 DAC is a research compound we track in our knowledge base but do not currently carry as an SKU. For sourcing inquiries or bulk institutional orders, contact our team. Meanwhile, browse the full catalog of ≥99% HPLC-verified peptides we do stock.
Same research goal
Related research compounds
Glossary entries describe research pharmacology for in-vitro and laboratory contexts only.







